Clinical Trial Update: Dupilumab and Milk OIT for the Treatment of Cow's Milk Allergy [Phase 2]

View source ↗

Summary

Phase 2 study evaluating dupilumab in combination with milk oral immunotherapy for cow's milk allergy was terminated; results were posted in January 2026.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cow Milk Allergy

Drugs mentioned

• Dupilumab (dupilumab)

Snippet

Sponsor: Andrew J Long, PharmD | Conditions: Allergies Food Milk | Phase 2 | Status: TERMINATED | Results posted: 2026-01-07